<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01473524</url>
  </required_header>
  <id_info>
    <org_study_id>747-301</org_study_id>
    <nct_id>NCT01473524</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Obeticholic Acid in Patients With Primary Biliary Cirrhosis</brief_title>
  <acronym>POISE</acronym>
  <official_title>A Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients With Primary Biliary Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intercept Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intercept Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigational drug, Obeticholic Acid (OCA) is a modified bile acid and FXR agonist. FXR
      is a key regulator of bile acid synthesis and transport. Bile acids are used by the body to
      help with digestion. It is hypothesized that regular treatment with OCA will improve liver
      function in persons with Primary Biliary Cirrhosis (PBC).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg OCA vs. Placebo</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg vs. Placebo</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 5-10 mg vs. Placebo</measure>
    <time_frame>12 Months</time_frame>
    <description>Proportion of subjects at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 5-10 mg vs. Placebo</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion of subjects at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alkaline Phosphatase Absolute Change From Baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Alkaline Phosphatase Absolute Change from Baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Bilirubin Absolute Change From Baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Total Bilirubin Absolute Change from Baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Direct Bilirubin Absolute Change From Baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Direct Bilirubin Absolute Change from Baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) Absolute Change From Baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Alanine Aminotransferase (ALT) Absolute Change from Baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) Absolute Change From Baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Aspartate Aminotransferase (AST) Absolute Change from Baseline to Month 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gamma-glutamyltransferase (GGT) Absolute Change From Baseline to Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>Gamma-glutamyltransferase (GGT) Absolute Change from Baseline to Month 12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Primary Biliary Cirrhosis</condition>
  <arm_group>
    <arm_group_label>OCA 5-10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OCA 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obeticholic Acid (OCA)</intervention_name>
    <arm_group_label>OCA 5-10 mg</arm_group_label>
    <arm_group_label>OCA 10 mg</arm_group_label>
    <other_name>6α-ethyl chenodeoxycholic acid (6-ECDCA)</other_name>
    <other_name>INT-747</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Definite or probable PBC diagnosis (consistent with American Association for the Study
             of Liver Disease [AASLD] and European Association for Study of the Liver [EASL]
             Practice Guidelines; [Lindor 2009; EASL 2009]), as demonstrated by the presence of ≥ 2
             of the following 3 diagnostic factors:

               -  History of elevated Alkaline Phosphatase levels for at least 6 months

               -  Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low
                  titer (&lt;1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or
                  antibodies against the major M2 components (PDC-E2, 2-oxo-glutaric acid
                  dehydrogenase complex)

               -  Liver biopsy consistent with PBC

          2. At least 1 of the following qualifying biochemistry values:

               -  ALP ≥ 1.67x upper limit of normal (ULN)

               -  Total bilirubin &gt; ULN but &lt; 2x ULN

          3. Age ≥ 18 years

          4. Taking ursodeoxycholic acid (UDCA) for at least 12 months (stable dose for ≥ 3 months)
             prior to Day 0, or unable to tolerate UDCA (no UDCA for ≥ 3 months) prior to Day 0.

          5. Contraception: Female patients must be postmenopausal, surgically sterile, or if
             premenopausal, be prepared to use ≥ 1 effective (≤ 1% failure rate) method of
             contraception during the trial and for 30 days after the end of treatment (EOT) visit.
             Effective methods of contraception are considered to be:

               -  Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection);
                  or

               -  Double barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with
                  spermicide; or

               -  Intrauterine device (IUD); or

               -  Vasectomy (partner)

          6. Must provide written informed consent and agree to comply with the trial protocol.

        Exclusion Criteria:

          1. History or presence of other concomitant liver diseases including:

               -  Hepatitis C virus (HCV) infection; patients with active hepatitis B (HBV)
                  infection will be excluded, however, patients who have seroconverted (Hbs Ag and
                  Hbe Ag negative) may be included after consultation with the medical monitor.

               -  Primary sclerosing cholangitis (PSC)

               -  Alcoholic liver disease

               -  Definite autoimmune liver disease or overlap hepatitis

               -  Nonalcoholic steatohepatitis (NASH)

               -  Gilbert's Syndrome (due to interpretability of bilirubin levels)

          2. Presence of clinical complications of PBC or clinically significant hepatic
             decompensation, including:

               -  History of liver transplantation, current placement on a liver transplant list or
                  current Model for End Stage Liver Disease (MELD) score ≥ 15

               -  Portal hypertension with complications, including: known gastric or large
                  esophageal varices, poorly controlled or diuretic resistant ascites, history of
                  variceal bleeds or related therapeutic or prophylactic interventions (e.g., beta
                  blockers, insertion of variceal bands or transjugular intrahepatic portosystemic
                  shunt [TIPS]), or hepatic encephalopathy

               -  Cirrhosis with complications, including history or presence of: spontaneous
                  bacterial peritonitis, hepatocellular carcinoma, bilirubin &gt; 2x ULN

               -  Hepatorenal syndrome (type I or II) or Screening serum creatinine &gt; 2 mg/dL (178
                  μmol/L)

          3. Patients with severe pruritus or those requiring systemic treatment for pruritus
             (e.g., with bile acid sequestrants [BAS] or rifampicin) within 2 months of Day 0 will
             be excluded

          4. Administration of the following medications is prohibited as specified below:

               -  Prohibited 6 months prior to Day 0 and throughout the trial (i.e., to last dose
                  to last dose and/or EOT): azathioprine, colchicine, cyclosporine, methotrexate,
                  mycophenolate mofetil, pentoxifylline; fenofibrate or other fibrates; budesonide
                  and other systemic corticosteroids; potentially hepatotoxic drugs (including
                  α-methyl-dopa, sodium valproic acid, isoniazide, or nitrofurantoin)

               -  Prohibited 12 months prior to Day 0 and throughout the trial (i.e., to last dose
                  to last dose and/or EOT): antibodies or immunotherapy directed against
                  interleukins or other cytokines or chemokines

          5. Patients who have previously participated in a clinical trial of OCA will not be
             allowed to participate

          6. History or presence of clinically concerning cardiac arrhythmias likely to affect
             survival during the trial, or prolongation of Screening (pretreatment) QT or QTc
             interval of &gt; 500 milliseconds (msec)

          7. If female: known pregnancy, or has a positive urine pregnancy test (confirmed by a
             positive serum pregnancy test), or lactating

          8. Known history of human immunodeficiency virus (HIV) infection

          9. Presence of any other disease or condition that is interfering with the absorption,
             distribution, metabolism, or excretion of drugs including bile salt metabolism in the
             intestine. Patients with inflammatory bowel disease or who have undergone gastric
             bypass procedures will be excluded (gastric lap band is acceptable).

         10. Medical conditions that may cause nonhepatic increases in ALP (e.g., Paget's disease)
             or which may diminish life expectancy to &lt; 2 years, including known cancers (except
             carcinomas in situ or other stable, relatively benign conditions such as chronic
             lymphatic leukemia)

         11. Other clinically significant medical conditions that are not well controlled or for
             which medication needs are anticipated to change during the trial

         12. Anticipated changes to current concomitant medications during the course of the trial

         13. History of alcohol abuse, defined as consumption of more than 210 mL of alcohol per
             week (i.e., the equivalent of 14 4-ounce (125 mL) glasses of wine or 14 12 ounce
             cans/bottles of beer), or other substance abuse within 1 year prior to Day 0

         14. Participation in another investigational drug, biologic, or medical device trial
             within 30 days prior to Screening

         15. History of noncompliance with medical regimens, or patients who are considered to be
             potentially unreliable

         16. Blood or plasma donation within 30 days prior to Day 0

         17. Mental instability or incompetence, such that the validity of informed consent or
             compliance with the trial is uncertain
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Shapiro, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Intercept Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University School of Medicine</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48377</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liver Institute of Virginia</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University/McGuire DVAMC</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Prince Alfred Hospital</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>B-3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital Liver Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM Hôpital St-Luc</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 3J4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Haut-Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>D-52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Friedrich-Alexander-Universität Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>D-91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Johann-Wolfgang Goethe Universität Frankfurt am Main</name>
      <address>
        <city>Frankfurt am Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>D-30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universitätsklinik</name>
      <address>
        <city>Heidelberg</city>
        <zip>D-69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastroenterologische Gemeinschaftspraxis, Dres. Felten / Hartmann / Hüppe</name>
      <address>
        <city>Herne</city>
        <zip>D-44623</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität München</name>
      <address>
        <city>München</city>
        <zip>D-81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Clinica - Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dip. Medicina Clinica- Università di Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova - Gastroenterologia</name>
      <address>
        <city>Padova PD</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUmc Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMC Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud, Nijmegen</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>All-Medicus</name>
      <address>
        <city>Katowice</city>
        <zip>40-660</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika Gastroenterologii i Hepatologii SP CSK im. prof. K. Gibinskiego SUM</name>
      <address>
        <city>Katowice</city>
        <zip>40-752</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Szpital Kliniczny nr 4 w Lublinie</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej &quot;SONOMED&quot;</name>
      <address>
        <city>Szczecin</city>
        <zip>70-361</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii - Instytut im. Marii Skłodowskiej - Curie, Klinika Gastroenterologii</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <zip>SE-41345</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bristol Royal Infirmary</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8HW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital Dundee</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forth Valley Royal Hospital</name>
      <address>
        <city>Larbert</city>
        <zip>FK5 4WR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester Royal Infirmary</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Cellular Medicine, Newcastle University</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE2 4 HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals NHS Trust</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 2UH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals Trust</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology. 2009 Jul;50(1):291-308. doi: 10.1002/hep.22906.</citation>
    <PMID>19554543</PMID>
  </reference>
  <results_reference>
    <citation>Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. N Engl J Med. 2016 Aug 18;375(7):631-43. doi: 10.1056/NEJMoa1509840.</citation>
    <PMID>27532829</PMID>
  </results_reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2011</study_first_submitted>
  <study_first_submitted_qc>November 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2011</study_first_posted>
  <results_first_submitted>December 20, 2016</results_first_submitted>
  <results_first_submitted_qc>December 20, 2016</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2017</results_first_posted>
  <last_update_submitted>March 9, 2018</last_update_submitted>
  <last_update_submitted_qc>March 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Primary Biliary Cholangitis</keyword>
  <keyword>Primary Biliary Cirrhosis</keyword>
  <keyword>PBC</keyword>
  <keyword>Cirrhosis</keyword>
  <keyword>Liver</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chenodeoxycholic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment into hospitals and physicians' clinics started JAN 2012 and completed DEC 2012.</recruitment_details>
      <pre_assignment_details>Screening interim allowed for pre-randomization eligibility assessment of 1 to 8 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OCA 5-10 mg</title>
          <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="P2">
          <title>OCA 10 mg</title>
          <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64"/>
                <participants group_id="P2" count="64"/>
                <participants group_id="P3" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>71 subjects were randomized in the OCA 5-10 mg group, however 1 subject never received treatment. Therefore, the Baseline Analysis Population of 70 subjects is the Intent-to-Treat Population</population>
      <group_list>
        <group group_id="B1">
          <title>OCA 5-10 mg</title>
          <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="B2">
          <title>OCA 10 mg</title>
          <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="70"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="216"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="176"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.8" spread="10.53"/>
                    <measurement group_id="B2" value="56.2" spread="11.00"/>
                    <measurement group_id="B3" value="55.5" spread="10.03"/>
                    <measurement group_id="B4" value="55.8" spread="10.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="196"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Austria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Australia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alkaline Phosphatase (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325.87" spread="116.238"/>
                    <measurement group_id="B2" value="316.34" spread="103.881"/>
                    <measurement group_id="B3" value="327.49" spread="115.014"/>
                    <measurement group_id="B4" value="323.19" spread="111.375"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total Bilirubin (umol/L)</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.192" spread="5.549"/>
                    <measurement group_id="B2" value="11.278" spread="6.634"/>
                    <measurement group_id="B3" value="11.757" spread="7.227"/>
                    <measurement group_id="B4" value="11.088" spread="6.522"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Direct Bilirubin (umol/L)</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.398" spread="4.528"/>
                    <measurement group_id="B2" value="4.868" spread="4.473"/>
                    <measurement group_id="B3" value="5.469" spread="6.214"/>
                    <measurement group_id="B4" value="4.919" spread="5.138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine Aminotransferase (ALT) (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.56" spread="39.037"/>
                    <measurement group_id="B2" value="56.31" spread="39.741"/>
                    <measurement group_id="B3" value="55.99" spread="30.312"/>
                    <measurement group_id="B4" value="57.9" spread="36.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate Aminotransferase (AST) (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.25" spread="25.289"/>
                    <measurement group_id="B2" value="50.49" spread="31.100"/>
                    <measurement group_id="B3" value="48.79" spread="22.449"/>
                    <measurement group_id="B4" value="50.49" spread="26.456"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gamma-Glutamyltransferase (GGT) (U/L)</title>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="252.83" spread="167.038"/>
                    <measurement group_id="B2" value="261.07" spread="207.396"/>
                    <measurement group_id="B3" value="309.58" spread="449.356"/>
                    <measurement group_id="B4" value="274.79" spread="302.673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg OCA vs. Placebo</title>
        <description>Proportion of subjects at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg OCA vs. Placebo</title>
          <description>Proportion of subjects at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 10 mg OCA. H1: The response rates are different between placebo and 10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran–Mantel–Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg vs. Placebo</title>
        <description>Proportion of subjects at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>6 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 10 mg vs. Placebo</title>
          <description>Proportion of subjects at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 10 mg OCA. H1: The response rates are different between placebo and 10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran–Mantel–Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 5-10 mg vs. Placebo</title>
        <description>Proportion of subjects at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>12 Months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 5-10 mg vs. Placebo</title>
          <description>Proportion of subjects at Month 12 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 5-10 mg OCA. H1: The response rates are different between placebo and 5-10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran–Mantel–Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 5-10 mg vs. Placebo</title>
        <description>Proportion of subjects at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
        <time_frame>6 Months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Composite Endpoint Alkaline Phosphatase and Total Bilirubin, 5-10 mg vs. Placebo</title>
          <description>Proportion of subjects at Month 6 with ALP &lt; 1.67x ULN and total bilirubin ≤ ULN and ALP decrease of ≥ 15% from baseline.</description>
          <population>Intent-to-Treat Population</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="70"/>
                <count group_id="O2" value="73"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>H0: The response rates are equal between placebo and 5-10 mg OCA. H1: The response rates are different between placebo and 5-10 mg OCA.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran–Mantel–Haenszel (CMH) General Association test stratified by randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alkaline Phosphatase Absolute Change From Baseline to Month 12</title>
        <description>Alkaline Phosphatase Absolute Change from Baseline to Month 12</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Alkaline Phosphatase Absolute Change From Baseline to Month 12</title>
          <description>Alkaline Phosphatase Absolute Change from Baseline to Month 12</description>
          <population>Intent-to-Treat Population</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-112.51" spread="14.36"/>
                    <measurement group_id="O2" value="-129.90" spread="14.60"/>
                    <measurement group_id="O3" value="-14.42" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Bilirubin Absolute Change From Baseline to Month 12</title>
        <description>Total Bilirubin Absolute Change from Baseline to Month 12</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Bilirubin Absolute Change From Baseline to Month 12</title>
          <description>Total Bilirubin Absolute Change from Baseline to Month 12</description>
          <population>Intent-to-Treat Population</population>
          <units>umol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.33" spread="0.68"/>
                    <measurement group_id="O2" value="-0.90" spread="0.71"/>
                    <measurement group_id="O3" value="1.98" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Direct Bilirubin Absolute Change From Baseline to Month 12</title>
        <description>Direct Bilirubin Absolute Change from Baseline to Month 12</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Direct Bilirubin Absolute Change From Baseline to Month 12</title>
          <description>Direct Bilirubin Absolute Change from Baseline to Month 12</description>
          <population>Intent-to-Treat Population</population>
          <units>umol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.13" spread="0.52"/>
                    <measurement group_id="O2" value="-0.49" spread="0.54"/>
                    <measurement group_id="O3" value="1.89" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) Absolute Change From Baseline to Month 12</title>
        <description>Alanine Aminotransferase (ALT) Absolute Change from Baseline to Month 12</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) Absolute Change From Baseline to Month 12</title>
          <description>Alanine Aminotransferase (ALT) Absolute Change from Baseline to Month 12</description>
          <population>Intent-to-Treat Population</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.26" spread="3.27"/>
                    <measurement group_id="O2" value="-25.31" spread="3.35"/>
                    <measurement group_id="O3" value="-4.95" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) Absolute Change From Baseline to Month 12</title>
        <description>Aspartate Aminotransferase (AST) Absolute Change from Baseline to Month 12</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double blind-period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) Absolute Change From Baseline to Month 12</title>
          <description>Aspartate Aminotransferase (AST) Absolute Change from Baseline to Month 12</description>
          <population>Intent-to-Treat Population</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.03" spread="4.17"/>
                    <measurement group_id="O2" value="-15.00" spread="4.28"/>
                    <measurement group_id="O3" value="1.04" spread="4.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Gamma-glutamyltransferase (GGT) Absolute Change From Baseline to Month 12</title>
        <description>Gamma-glutamyltransferase (GGT) Absolute Change from Baseline to Month 12</description>
        <time_frame>12 months</time_frame>
        <population>Intent-to-Treat Population</population>
        <group_list>
          <group group_id="O1">
            <title>OCA 5-10 mg</title>
            <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period.
After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O2">
            <title>OCA 10 mg</title>
            <description>OCA 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>One tablet daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
          </group>
        </group_list>
        <measure>
          <title>Gamma-glutamyltransferase (GGT) Absolute Change From Baseline to Month 12</title>
          <description>Gamma-glutamyltransferase (GGT) Absolute Change from Baseline to Month 12</description>
          <population>Intent-to-Treat Population</population>
          <units>U/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="62"/>
                <count group_id="O3" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-140.83" spread="24.70"/>
                    <measurement group_id="O2" value="-176.66" spread="25.58"/>
                    <measurement group_id="O3" value="6.70" spread="25.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>ANCOVA model with baseline value as a covariate and fixed effects for treatment and randomization strata factor.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From informed consent to end of study participation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>OCA 5-10 mg</title>
          <description>OCA 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double blind-period.
After completion of the 1 year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="E2">
          <title>OCA 10 mg</title>
          <description>OCA 10 mg for double-blind period. After completion of the 1 year double-blind period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>One tablet daily for double-blind period. After completion of the 1 year double-blind period period subjects will be offered the opportunity to enter an open label long term safety extension for up to 5 years beginning at 5 mg OCA. Doses up to 25 mg daily will be evaluated.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sick sinus syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Varices oesophageal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Splenic artery aneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 15.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="63" subjects_at_risk="70"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" events="18" subjects_affected="9" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="73"/>
                <counts group_id="E3" events="13" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="70"/>
                <counts group_id="E2" events="25" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E3" events="12" subjects_affected="10" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="27" subjects_affected="17" subjects_at_risk="70"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="73"/>
                <counts group_id="E3" events="19" subjects_affected="13" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="15" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="26" subjects_affected="12" subjects_at_risk="70"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="16" subjects_affected="13" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="70"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="70"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="93" subjects_affected="39" subjects_at_risk="70"/>
                <counts group_id="E2" events="99" subjects_affected="50" subjects_at_risk="73"/>
                <counts group_id="E3" events="49" subjects_affected="28" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="70"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="73"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="70"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="73"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Principal Investigators must wait 18 months after the study ends to publish their results and a multi-center publication must come first. The sponsor has a 45 day review period with the option to extend to an additional 90 days.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Information</name_or_title>
      <organization>Intercept Pharmaceuticals, Inc.</organization>
      <phone>844-782-4278</phone>
      <email>medinfo@interceptpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

